ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC) in a trial conducted by Alliance Foundation Trials
All patients who switched treatment had been randomized to enzalutamide and later moved to NUBEQA, driven predominantly by objective or subjective cognitive decline
Primary results from the Phase II ARACOG trial were presented as an oral abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and highlighted in the Press Program
Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA® (darolutamide; n=55) experienced significantly less decline in objective cognitive performance over 24 weeks compared with those treated with enzalutamide (n=56).
